Victory Capital Management
GTHX

Victory Capital Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Victory Capital Management’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-7,304
Closed -$80K – 3389
2020
Q1 		$80K Buy
7,304
+2,658
+57% +$49.6K ﹤0.01% 2606
2019
Q4 		$123K Buy
4,646
+531
+13% +$12.4K ﹤0.01% 2477
2019
Q3 		$94K Buy
+4,115
New +$130K ﹤0.01% 2459
2018
Q4 		– Sell
-34,210
Closed -$1.79M – 1824
2018
Q3 		$1.79M Sell
34,210
-10,260
-23% -$559K ﹤0.01% 1117
2018
Q2 		$1.93M Sell
44,470
-2,400
-5% -$103K ﹤0.01% 1084
2018
Q1 		$1.74M Sell
46,870
-4,720
-9% -$126K ﹤0.01% 1103
2017
Q4 		$1.02M Buy
51,590
+1,360
+3% +$29.2K ﹤0.01% 1221
2017
Q3 		$1.25M Sell
50,230
-770
-2% -$14.2K ﹤0.01% 1155
2017
Q2 		$889K Buy
+51,000
New +$892K ﹤0.01% 1212

Other funds holding GTHX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Victory Capital Management's GTHX Position: Q2 2020 in Review

Victory Capital Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2020, closing a stake of 7,304 shares — an estimated $80K sold.

Victory Capital Management first reported a position in GTHX in Q2 2017 and held it in 9 quarters. The position peaked at $1.93M in Q2 2018. 100 funds tracked by Wall St. Rank hold GTHX as of Q2 2020.

  • Victory Capital Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 7,304 G1 Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $80K.
  • Victory Capital Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2017 and held it in 9 quarters.
  • Victory Capital Management's G1 Therapeutics, Inc. Common Stock position peaked at $1.93M in Q2 2018.
  • 100 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.